dsm-firmenich present the first worldwide results comparing their novel CBD formulation CBtru® to Epidiolex.
This Phase I clinical trial shows CBtru® offers equivalent or better bioavailability than the current gold standard, with less variability between subjects and reduced food dependency. This solid formulation breakthrough could transform CBD medication delivery with more convenient dosage options and improved patient experience.
Speaker:
This session lasts 20 min.
Discover how dsm-firmenich and Bayer reduced vitamin C’s carbon footprint by 49% through renewable energy, process innovation, and sustainable pharma collaboration.
Discover how dsm-firmenich is tackling the challenge of bitter medicine with a receptor-based technology designed to elevate drug palatability and improve patient adherence.
Explore how dsm-firmenich can help pharma raise the bar in patient-centricity and sustainability.
Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.
Don’t just take our word for it. Discover how our solutions can support your product development journey.
Customized blends of functional ingredients in one single, efficient premix.
Streamline your product development process and get to market faster.
From trade shows to conferences and other industry events, find out where you can meet us next.
Talking Nutrition, Health & Care
Explore new science, consumer insights, industry news and more in our latest articles.
Discover educational whitepapers, webinars, publications and technical information.
Request samples, place orders and view product documentation.